6 O
. O

ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
5 O
% O
and O
at O
least O
twice O
as O
high O
on O
HETLIOZ O
than O
on O
placebo O
) O
were O
headache O
, O
increased O
alanine O
aminotransferase O
, O
nightmares O
or O
unusual O
dreams O
, O
and O
upper O
respiratory O
or O
urinary O
tract O
infection O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Vanda O
Pharmaceuticals O
Inc O
. O
at O
1-844-438-5469 O
or O
www.hetlioz.com O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

A O
total O
of O
1346 O
subjects O
were O
treated O
with O
at O
least O
one O
dose O
of O
HETLIOZ O
, O
of O
which O
139 O
were O
treated O
for O
> O
26 O
weeks O
and O
93 O
were O
treated O
for O
> O
1 O
year O
. O

A O
26-week O
, O
parallel-arm O
placebo-controlled O
study O
( O
Study O
1 O
) O
evaluated O
HETLIOZ O
( O
n=42 O
) O
compared O
to O
placebo O
( O
n=42 O
) O
in O
patients O
with O
Non-24 O
. O

A O
randomized-withdrawal O
, O
placebo- O
controlled O
study O
of O
8 O
weeks O
duration O
( O
Study O
2 O
) O
also O
evaluated O
HETLIOZ O
( O
n=10 O
) O
, O
compared O
to O
placebo O
( O
n=10 O
) O
, O
in O
patients O
with O
Non-24 O
. O

In O
placebo-controlled O
studies O
, O
6 O
% O
of O
patients O
exposed O
to O
HETLIOZ O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
compared O
with O
4 O
% O
of O
patients O
who O
received O
placebo O
. O

Table O
1 O
shows O
the O
incidence O
of O
adverse O
reactions O
from O
Study O
1 O
. O

*Adverse O
reactions O
with O
an O
incidence O
> O
5 O
% O
and O
at O
least O
twice O
as O
high O
on O
HETLIOZ O
than O
on O
placebo O
are O
displayed O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
Study O
1 O
HETLIOZN=42 O
PlaceboN=42 O
Headache B-OSE_Labeled_AE
17 O
% O
7 O
% O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
% O
5 O
% O
Nightmare B-OSE_Labeled_AE
/ O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
10 O
% O
0 O
% O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
% O
0 O
% O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
% O
2 O
% O

